Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

NCT01023880 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT01023880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01023880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Lead sponsor
Cephalon
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2010
Completion date
January 31, 2013
Enrollment
62 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma